Fair Value Calculator Fair Value Calculator
EN DE

0544 (0544) Fair Value & Analysis

Industrials · Market cap HK$72.1M

0 0544 0544 · HK
PriceHK$1.61
Fair ValueHK$2.58
Upside+60.2%
Quality48/100
Evidence: Medium Range HK$1.64 – HK$2.58

Fair value as of: Jul 2, 2026

From 12 valuation models · updated today

Share price −19.5% over the past month.

Price vs Fair Value (12 months)

HK$2.50 HK$0.6300 Fair Value HK$2.58 Jun 2025 Jun 2026

12‑month range HK$0.6300 – HK$2.50 · fair‑value band HK$1.64 – HK$2.58 · the HK$1.61 price screens below the HK$2.58 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0544 (0544) currently trades at HK$1.61, while our model-based Fair Value estimate is HK$2.58 — implying the stock looks roughly 60.2% undervalued today. We read business quality at 48/100 (below-average quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 0544 generated revenue of HK$150M at a net margin of -48.2%. Revenue declined 22.8% year over year. Net debt stands at HK$514M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$150M
Revenue growth (YoY) -22.8%
Net margin -48.2%
Return on equity -189%
Free cash flow HK$12.3M FY2025
Operating margin -22.1%
More key figures
EPS (TTM) HK$-1.27
EPS growth (YoY) +410%
Net debt HK$514M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0544 reported revenue of HK$150M in FY2025 versus HK$235M in FY2021, a compound −10.7%/yr. Reported net income was −HK$72.1M in FY2025.

Revenue −10.7%/yr
FY21 HK$235M
FY22 HK$273M
FY23 HK$298M
FY24 HK$219M
FY25 HK$150M
Net income
FY21 −HK$80.3M
FY22 HK$4.8M
FY23 HK$5.7M
FY24 −HK$40.2M
FY25 −HK$72.1M

Is 0544 fairly valued? → Check now

Similar stocks

6 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Cintas Corporation CTAS $169.45 $82.75 -51%
RELX PLC R1EL34 R$45.28 R$23.22 -49%
Thomson Reuters Corporation TRI C$108.50 C$70.40 -35%
Copart, Inc CPRT $30.77 $28.89 -6%
Global Payments Inc GPN $65.09 $70.80 +9%
UL Solutions Inc ULS $89.71 $30.99 -65%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 0544 (0544) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$2.58 versus a price of HK$1.61 — about +60% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 0544?
Our model-based fair value for 0544 is HK$2.58 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.61.
What is the quality score of 0544?
0544 has a Quality Score of 48/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 0544 (0544)?
0544 reported trailing-twelve-month revenue of about HK$150M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 0544?
The net profit margin of 0544 is about -48.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.